Prevention by 5-HT1A receptor agonists of restraint stress- and yohimbine-induced release of cholecystokinin in the frontal cortex of the freely moving rat

被引:22
作者
Becker, C
Hamon, M
Benoliel, JJ
机构
[1] Fac Med Pitie Salpetriere, INSERM, U288, F-75634 Paris 13, France
[2] Fac Med Pitie Salpetriere, Serv Biochim Med, F-75634 Paris, France
关键词
cholecystokinin; in vivo microdialysis; frontal cortex; 5-H-1A receptor agonists; restraint stress; yohimbine-induced anxiety related behaviour;
D O I
10.1016/S0028-3908(98)00209-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In line with the idea that cholecystokinin (CCK) is involved in anxiety-related behaviours, previous investigations showed that stressful conditions and an 'anxiogenic' drug, yohimbine, increased the cortical release of CCK like-material (CCKLM) in awake rats, and that this effect could be prevented by diazepam. Here, we investigated whether other anxiolytic drugs such as 5-HT1A receptor agonists could also affect cortical CCKLM release. Indeed, neither buspirone (1 mg/kg i.p.), alnespirone (1 mg/kg i.p.) nor lesopitron (3 mg/kg i.p.) affected, on their own, CCKLM release. However, pretreatment with the latter drugs completely abolished the stimulatory effect of restraint stress on the peptide outflow. As expected of the involvement of 5-HT1A receptors, tertatolol (10 mg/kg i.p) markedly reduced the inhibitory effect of buspirone on restraint stress-evoked CCKLM overflow. On the other hand, pretreatment with buspirone, alnespirone or lesopitron also inhibited the stimulatory effect of yohimbine (5 mg/kg i.p.) on cortical CCKLM outflow. These data support the idea that the anxiolytic action of 5-HT1A receptor agonists could be mediated, at least partly, through their inhibitory influence on cortical CCK-ergic systems. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 39 条
[1]   ANXIOGENIC PROPERTIES OF YOHIMBINE .1. BEHAVIORAL, PHYSIOLOGICAL AND BIOCHEMICAL MEASURES [J].
ALBUS, M ;
ZAHN, TP ;
BREIER, A .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1992, 241 (06) :337-344
[2]   The effect of central and systemic injection of the 5-HT1A receptor agonist 8-OHDPAT and the 5-HT1A receptor antagonist WAY100635 on periaqueductal grey-induced defence behaviour [J].
Beckett, S ;
Marsden, CA .
JOURNAL OF PSYCHOPHARMACOLOGY, 1997, 11 (01) :35-40
[3]   GABA, ACTING AT BOTH GABA(A) AND GABA(B) RECEPTORS, INHIBITS THE RELEASE OF CHOLECYSTOKININ-LIKE MATERIAL FROM THE RAT SPINAL-CORD INVITRO [J].
BENOLIEL, JJ ;
BOURGOIN, S ;
MAUBORGNE, A ;
POHL, M ;
LEGRAND, JC ;
HAMON, M ;
CESSELIN, F .
BRAIN RESEARCH, 1992, 590 (1-2) :255-262
[4]  
BRADWEJN J, 1994, ARCH GEN PSYCHIAT, V51, P486
[5]   EFFECTS OF 5-HT1A RECEPTOR LIGANDS ON A SAFETY SIGNAL WITHDRAWAL PROCEDURE OF CONFLICT IN THE RAT [J].
CHARRIER, D ;
DANGOUMAU, L ;
HAMON, M ;
PUECH, AJ ;
THIEBOT, MH .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 48 (01) :281-289
[6]   THE PROFILES OF INTERACTION OF YOHIMBINE WITH ANXIOLYTIC AND PUTATIVE ANXIOLYTIC AGENTS TO MODIFY 5-HT RELEASE IN THE FRONTAL-CORTEX OF FREELY-MOVING RATS [J].
CHENG, CHK ;
COSTALL, B ;
GE, J ;
NAYLOR, RJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 (03) :1079-1084
[7]   ANXIOLYTIC EFFECTS OF CCK-B ANTAGONISTS [J].
COSTALL, B ;
DOMENEY, AM ;
HUGHES, J ;
KELLY, ME ;
NAYLOR, RJ ;
WOODRUFF, GN .
NEUROPEPTIDES, 1991, 19 :65-73
[8]   HETEROGENEITY OF CCK-B RECEPTORS INVOLVED IN ANIMAL-MODELS OF ANXIETY [J].
DERRIEN, M ;
MCCORTTRANCHEPAIN, I ;
DUCOS, B ;
ROQUES, BP ;
DURIEUX, C .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 49 (01) :133-141
[9]  
DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1
[10]   5-HYDROXYTRYPTAMINE-INTERACTING DRUGS IN ANIMAL-MODELS OF ANXIETY DISORDERS - MORE THAN 30 YEARS OF RESEARCH [J].
GRIEBEL, G .
PHARMACOLOGY & THERAPEUTICS, 1995, 65 (03) :319-395